Enfortumab vedotin-pembrolizumab shows durability advantage over chemotherapy at three-year follow-up in bladder cancer trial EV-302.

Regeneron will present updated C-POST overall survival data for adjuvant cemiplimab in high-risk CSCC at ESMO 2026 on October...

CDER's new Office of Innovation and Clinical Trial Modernization fuses AI and RWE policy under one roof. That structural...

Most sites undercharge on research-paid items because no one reconciles the sponsor budget against the charge master. Here is...

FDA extended its denecimig BLA review over unnamed facility remediation failures, exposing the manufacturing blind spot that nearly every...

A dual-cohort Lancet Psychiatry study links CYP2D6 poor metabolizer status to venlafaxine treatment failure, pressing sponsors to rethink IND...

Headlands Research Portland site marks 50 years of continuous Alzheimer's trials, contributing to every FDA-approved medication class since 1993.

Advarra's IRB chief targets pre-review delays as the next efficiency frontier to reduce waiting time for researchers and trial...

Forward Therapeutics' FT2109 advances to Phase 2 after clearing Phase 1 with once-daily oral dosing and a supportive safety...

Coya Therapeutics completes enrollment of 120 patients in COYA 302 ALS trial testing an immunomodulatory approach to slow neuroinflammation.